Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-4209-7
Abstract: PurposePeptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses to the critical organs and undertreatment of the majority of… read more here.
Keywords: initial results; response; 177lu octreotate; prrt trial ... See more keywords
Transcriptional effects of 177Lu-octreotate therapy using a priming treatment schedule on GOT1 tumor in nude mice
Sign Up to like & getrecommendations! Published in 2019 at "EJNMMI Research"
DOI: 10.1186/s13550-019-0500-2
Abstract: Background177Lu-octreotate is used for therapy of somatostatin receptor expressing neuroendocrine tumors with promising results, although complete tumor remission is rarely seen. Previous studies on nude mice bearing the human small intestine neuroendocrine tumor, GOT1, have… read more here.
Keywords: schedule; treatment; nude mice; 177lu octreotate ... See more keywords
Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor
Sign Up to like & getrecommendations! Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.25266
Abstract: For patients with inoperable neuroendocrine tumors (NETs) expressing somatostatin receptors, peptide receptor radionuclide therapy (PRRT) with 177Lu-[DOTA0-Tyr3]-octreotate (177Lu-octreotate) is one of the most promising targeted therapeutic options but it rarely achieves cure. Therefore, different approaches… read more here.
Keywords: 177lu octreotate; octreotate; receptor radionuclide; radionuclide therapy ... See more keywords
Hyperfractionated Treatment with 177Lu-Octreotate Increases Tumor Response in Human Small-Intestine Neuroendocrine GOT1 Tumor Model
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14010235
Abstract: Simple Summary Neuroendocrine tumors are slow growing and initially associated with vague symptoms and, therefore, often spread in the patient’s body at diagnosis, leading to a poor prognosis without means of curation through surgery. Although… read more here.
Keywords: tumor response; 177lu octreotate; human small; treatment ... See more keywords